BTMD biote Corp.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1819253 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.6%
TTM net income YoY-106.7%
TTM EPS YoY-108.9%
Revenue 3-yr CAGR-1.0%
Net income 3-yr CAGR—
Margins
Gross margin67.5%
Operating margin5.0%
Net margin-1.1%
FCF margin4.1%
EBITDA margin6.6%
Returns
ROE—
ROA-1.8%
ROIC (approx.)18.5%
Asset turnover1.68x
Leverage & solvency
Liabilities / assets156.6%
Debt / equity—
Current ratio1.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-7.26x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue3.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $192.22M | $197.19M |
| Cost of revenue | $54.86M | $58.13M |
| Gross profit | $137.36M | $139.06M |
| SG&A expense | $101.81M | $107.45M |
| Operating income | $35.55M | $31.61M |
| Pretax income | $37.58M | $1.02M |
| Income tax | $5.99M | $970,000 |
| Net income | $27.05M | $3.16M |
| EBITDA | $39.22M | $35.19M |
| EPS (basic) | 0.86 | 0.09 |
| EPS (diluted) | 0.74 | 0.09 |
| Weighted avg. shares (diluted) | 36.67M | 34.27M |
| Balance sheet | ||
| Cash & equivalents | $24.12M | $39.34M |
| Receivables | $6.87M | $7.63M |
| Inventory | $19.06M | $14.85M |
| Current assets | $54.67M | $68.13M |
| PP&E, net | $10.75M | $6.97M |
| Goodwill | $5.83M | $5.83M |
| Intangibles | $4.27M | $5.50M |
| Total assets | $107.61M | $122.37M |
| Current liabilities | $44.99M | $51.51M |
| Short-term debt | $6.25M | $6.25M |
| Long-term debt | $95.78M | $101.20M |
| Total debt | $102.03M | $107.45M |
| Total liabilities | $158.01M | $224.57M |
| Shareholders' equity | -$58.54M | -$105.93M |
| Net debt | $77.91M | $68.11M |
| Cash flow statement | ||
| Operating cash flow | $35.19M | $45.24M |
| Capital expenditure | $5.01M | $6.43M |
| Free cash flow | $30.18M | $38.81M |
| Investing cash flow | -$6.86M | -$18.80M |
| Financing cash flow | -$43.55M | -$76.08M |
| Depreciation & amortization | $3.67M | $3.57M |
| Stock-based compensation | $8.92M | $8.73M |
| Dividends paid | $1.73M | $4.74M |
| Share buybacks | $3.37M | $5.60M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.